Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 6.49 is 31% below its 5-year average of 9.45, near the low end of its 5-year range (5.35–17.17).
As of the fiscal period ended Tuesday, June 30, 2026. 5.90% above its 12-month average of 6.13.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 6.49.
QUICK RATIO (ACID-TEST)
6.49
QUICK RATIO (ACID-TEST) AVG TTM
6.13
QUICK RATIO (ACID-TEST) AVG 3Y
7.65
QUICK RATIO (ACID-TEST) AVG 5Y
9.45
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
+5.90%
CURRENT VS 3Y AVG
-15.23%
CURRENT VS 5Y AVG
-31.39%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
2.99
median of 592 covered companies
CURRENT VS SECTOR MEDIAN
+116.95%
vs the sector median at left
Caribou Biosciences, Inc.
Market Cap
$116.54M
Quick Ratio (Acid-Test)
6.49
TTM Avg
6.13
3Y Avg
7.65
5Y Avg
9.45
Market Cap
$116.57M
Quick Ratio (Acid-Test)
1.98
TTM Avg
1.40
3Y Avg
1.60
5Y Avg
1.70
Market Cap
$116.83M
Quick Ratio (Acid-Test)
13.31
TTM Avg
17.30
3Y Avg
10.78
5Y Avg
9.73
Market Cap
$114.79M
Quick Ratio (Acid-Test)
2.39
TTM Avg
3.50
3Y Avg
2.69
5Y Avg
1.97
Market Cap
$114.62M
Quick Ratio (Acid-Test)
11.47
TTM Avg
9.04
3Y Avg
10.96
5Y Avg
10.73
Market Cap
$120.24M
Quick Ratio (Acid-Test)
0.18
TTM Avg
2.21
3Y Avg
2.68
5Y Avg
2.62
Market Cap
$112.52M
Quick Ratio (Acid-Test)
1.31
TTM Avg
1.18
3Y Avg
1.49
5Y Avg
3.22
Market Cap
$112.36M
Quick Ratio (Acid-Test)
13.40
TTM Avg
10.04
3Y Avg
7.53
5Y Avg
8.95
Market Cap
$121.25M
Quick Ratio (Acid-Test)
10.21
TTM Avg
11.59
3Y Avg
10.00
5Y Avg
8.96
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Caribou Biosciences, Inc. (CRBU) | $116.54M | 6.49 | 6.13 | 7.65 | 9.45 |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $116.57M | 1.98 | 1.40 | 1.60 | 1.70 |
| LENZ Therapeutics, Inc. (LENZ)vs › | $116.83M | 13.31 | 17.30 | 10.78 | 9.73 |
| Genelux Corporation (GNLX)vs › | $114.79M | 2.39 | 3.50 | 2.69 | 1.97 |
| MaxCyte, Inc. (MXCT)vs › | $114.62M | 11.47 | 9.04 | 10.96 | 10.73 |
| TuHURA Biosciences, Inc. (HURA)vs › | $120.24M | 0.18 | 2.21 | 2.68 | 2.62 |
| Lucid Diagnostics Inc. (LUCD)vs › | $112.52M | 1.31 | 1.18 | 1.49 | 3.22 |
| Coya Therapeutics, Inc. (COYA)vs › | $112.36M | 13.40 | 10.04 | 7.53 | 8.95 |
| enGene Holdings Inc. (ENGN)vs › | $121.25M | 10.21 | 11.59 | 10.00 | 8.96 |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $110.73M | 0.96 | 0.94 | 1.06 | 1.28 |
Quick Ratio
6.49
Excludes inventory
Current Ratio
6.49
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 6.49 |
| 2026-03-31 | 6.22 |
| 2025-12-31 | 5.71 |
| 2025-09-30 | 5.54 |
| 2025-06-30 | 6.66 |
| 2025-03-31 | 7.63 |
| 2024-12-31 | 7.16 |
| 2024-09-30 | 7.38 |
| 2024-06-30 | 8.75 |
| 2024-03-31 | 10.49 |
| 2023-12-31 | 11.97 |
| 2023-09-30 | 14.27 |
| 2023-06-30 | 7.81 |
| 2023-03-31 | 8.84 |
| 2022-12-31 | 9.25 |
| 2022-09-30 | 10.65 |
| 2022-06-30 | 12.23 |
| 2022-03-31 | 13.80 |
| 2021-12-31 | 15.15 |
| 2021-09-30 | 17.17 |
| 2021-06-30 | 5.35 |
| 2021-03-31 | 7.02 |
| 2020-12-31 | 1.96 |
| 2020-09-30 | 0.00 |
| 2020-06-30 | 0.00 |
| 2020-03-31 | 0.00 |
